WO2010126670A3 - Compositions and methods for screening and using compounds antagonizing spore-surface interactions - Google Patents

Compositions and methods for screening and using compounds antagonizing spore-surface interactions Download PDF

Info

Publication number
WO2010126670A3
WO2010126670A3 PCT/US2010/028902 US2010028902W WO2010126670A3 WO 2010126670 A3 WO2010126670 A3 WO 2010126670A3 US 2010028902 W US2010028902 W US 2010028902W WO 2010126670 A3 WO2010126670 A3 WO 2010126670A3
Authority
WO
WIPO (PCT)
Prior art keywords
exosporium
proteins
attachment
microbial
spore
Prior art date
Application number
PCT/US2010/028902
Other languages
French (fr)
Other versions
WO2010126670A2 (en
WO2010126670A9 (en
Inventor
David R. Macinga
James Edmund Bingham
Sarah L. Edmonds
Original Assignee
Gojo Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gojo Industries, Inc. filed Critical Gojo Industries, Inc.
Priority to CA2756760A priority Critical patent/CA2756760A1/en
Priority to ES10745031.4T priority patent/ES2544435T3/en
Priority to JP2012502303A priority patent/JP5911421B2/en
Priority to CN2010800140986A priority patent/CN102388064A/en
Priority to BRPI1014121A priority patent/BRPI1014121A2/en
Priority to AU2010241947A priority patent/AU2010241947B2/en
Priority to DK10745031.4T priority patent/DK2411410T3/en
Priority to EP10745031.4A priority patent/EP2411410B1/en
Publication of WO2010126670A2 publication Critical patent/WO2010126670A2/en
Publication of WO2010126670A3 publication Critical patent/WO2010126670A3/en
Publication of WO2010126670A9 publication Critical patent/WO2010126670A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material

Abstract

The present invention provides genes encoding novel microbial proteins (i.e., for example, exosporium genes and proteins) that mediate the attachment of microbial spores to surfaces. Specific fragments of these microbial spore proteins may be utilized to inhibit the attachment of microbial spores to surfaces, thereby providing an infection control agent. The invention provides recombinant expression vectors comprising genes encoding exosporium proteins, as well as host cells containing these expression vectors. Further provided herein are screening methods for identifying infection control compositions comprising exosporium proteins that inhibit bacterial spore attachment to either bodily tissues or solid surfaces. Additionally, the invention provides for the use of nucleic acid inhibitors of exosporium protein expression by hybridizing with nucleic acid sequences encoding exosporium protiens as well as with exosprorium mRNA. The invention further describes monoclonal and polyclonal antibodies having affinity for exosporium protiens.
PCT/US2010/028902 2009-03-27 2010-03-26 Compositions and methods for screening and using compounds antagonizing spore-surface interactions WO2010126670A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2756760A CA2756760A1 (en) 2009-03-27 2010-03-26 Compositions and methods for screening and using compounds antagonizing spore-surface interactions
ES10745031.4T ES2544435T3 (en) 2009-03-27 2010-03-26 Compositions and methods for examining and using compounds that antagonize spore-surface interactions
JP2012502303A JP5911421B2 (en) 2009-03-27 2010-03-26 Compositions and methods for screening for and using compounds that antagonize spore-surface interactions
CN2010800140986A CN102388064A (en) 2009-03-27 2010-03-26 Compositions and methods for screening and using compounds antagonizing spore-surface interactions
BRPI1014121A BRPI1014121A2 (en) 2009-03-27 2010-03-26 compositions and methods for investigating and using compounds that antagonize sporo-surface interactions
AU2010241947A AU2010241947B2 (en) 2009-03-27 2010-03-26 Compositions and methods for screening and using compounds antagonizing spore-surface interactions
DK10745031.4T DK2411410T3 (en) 2009-03-27 2010-03-26 Compositions and methods for screening and use of compounds which counteract the track-surface interactions
EP10745031.4A EP2411410B1 (en) 2009-03-27 2010-03-26 Compositions and methods for screening and using compounds antagonizing spore-surface interactions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16415409P 2009-03-27 2009-03-27
US61/164,154 2009-03-27

Publications (3)

Publication Number Publication Date
WO2010126670A2 WO2010126670A2 (en) 2010-11-04
WO2010126670A3 true WO2010126670A3 (en) 2011-03-31
WO2010126670A9 WO2010126670A9 (en) 2011-06-30

Family

ID=43032739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/028902 WO2010126670A2 (en) 2009-03-27 2010-03-26 Compositions and methods for screening and using compounds antagonizing spore-surface interactions

Country Status (13)

Country Link
US (1) US20100291100A1 (en)
EP (1) EP2411410B1 (en)
JP (1) JP5911421B2 (en)
KR (1) KR20110140128A (en)
CN (1) CN102388064A (en)
AU (1) AU2010241947B2 (en)
BR (1) BRPI1014121A2 (en)
CA (1) CA2756760A1 (en)
DK (1) DK2411410T3 (en)
ES (1) ES2544435T3 (en)
PT (1) PT2411410E (en)
TW (1) TW201039841A (en)
WO (1) WO2010126670A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133251B2 (en) * 2008-02-22 2015-09-15 The Curators Of The University Of Missouri Bacillus based delivery system and methods of use
US20130243794A1 (en) * 2010-12-03 2013-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses
CN103608464A (en) * 2010-12-29 2014-02-26 卡恩基因公司 Clostridium difficile antigens
GB2491117A (en) 2011-05-20 2012-11-28 Royal Holloway & Bedford New College Coat proteins from Clostridium and Bacillus species
US9573980B2 (en) 2013-03-15 2017-02-21 Spogen Biotech Inc. Fusion proteins and methods for stimulating plant growth, protecting plants from pathogens, and immobilizing Bacillus spores on plant roots
WO2014193237A2 (en) * 2013-05-30 2014-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc C diff protease
US20160250283A1 (en) * 2013-10-23 2016-09-01 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
BR122023020803A2 (en) 2014-09-17 2024-01-23 Spogen Biotech Inc. RECOMBINANT BACILLUS BACTERIA AND ITS FORMULATION
CA3019732A1 (en) * 2016-04-05 2017-10-12 Nch Corporation Nutrient rich germinant composition and spore incubation method
US11400121B2 (en) 2017-01-05 2022-08-02 The University Of Chicago Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
CN109706101B (en) * 2019-02-01 2022-10-11 东华大学 Sporosarcina psychrophilum and application thereof
EP3980553A4 (en) 2019-06-05 2024-02-28 Liv Process Inc Aptamers against clostridium difficile
CN110879209A (en) * 2019-12-09 2020-03-13 济南大学 Rapid detection method of gamma-aminobutyric acid
CN114807194B (en) * 2020-08-31 2023-05-12 南京工业大学 Method for improving protein expression efficiency in clostridium
US11898146B2 (en) * 2020-12-03 2024-02-13 Liv Process, Inc. Aptamers against Clostridium difficile, compositions comprising aptamers against Clostridium difficile and methods of using the same
WO2022209994A1 (en) * 2021-03-30 2022-10-06 旭化成株式会社 Recombinant polypeptide having acyl-coa compound reducing activity
CN113247946B (en) * 2021-04-22 2022-07-05 哈尔滨工业大学 Self-assembled nano biocatalyst, preparation method thereof and application thereof in butanol production
CN113308431B (en) * 2021-06-15 2022-09-16 广西大学 Transplanting and dispersing method for botrytis cinerea conidia
CN113278578B (en) * 2021-06-15 2022-09-16 广西大学 Transplanting method of rice blast bacterium conidia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007148065A2 (en) * 2006-06-23 2007-12-27 The Secretary Of State For Defence Antibody for anthrax

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28778E (en) * 1969-12-23 1976-04-20 West Laboratories, Inc. Phenolic synthetic detergent-disinfectant
NL7018669A (en) * 1969-12-23 1971-06-25
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) * 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) * 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4632772A (en) * 1982-02-22 1986-12-30 Dexide, Inc. Mild antimicrobial detergent composition
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US5506337A (en) * 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5288486A (en) 1985-10-28 1994-02-22 Calgon Corporation Alcohol-based antimicrobial compositions
CA1291031C (en) * 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US5169862A (en) 1989-07-07 1992-12-08 Peptide Technologies Corporation Analogs of viscosin and their uses
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5114978A (en) * 1990-10-15 1992-05-19 Rhone-Poulenc Surfactants And Specialties, L.P. Anhydrous blends of p-chloro-m-xylenol in surfactant mixtures
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5541061A (en) * 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5559410A (en) 1992-12-17 1996-09-24 Valeo Systemes D'essuyage Device for controlling the function of an electric starting motor for a windshield wiper of a rear window of an automotive vehicle and for supplying an electric motor particularly to activate the windshield
US5576220A (en) * 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5539085A (en) 1993-08-20 1996-07-23 Onyx Pharmaceuticals, Inc. Bcl-2 and R-ras complex
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) * 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) * 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5635462A (en) * 1994-07-08 1997-06-03 Gojo Industries, Inc. Antimicrobial cleansing compositions
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US5585639A (en) * 1995-07-27 1996-12-17 Hewlett-Packard Company Optical scanning apparatus
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
WO1997023782A1 (en) 1995-12-22 1997-07-03 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
US7655252B2 (en) * 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
AU2001245997A1 (en) * 2000-02-01 2001-08-14 Arthur D. Little, Inc. Chemical and/or biological decontamination system
US6656919B1 (en) * 2002-01-11 2003-12-02 Clarence L. Baugh Method and a product for the rapid decontamination and sterilization of bacterial endospores
US7192601B2 (en) * 2002-01-18 2007-03-20 Walker Edward B Antimicrobial and sporicidal composition
WO2005013898A2 (en) * 2003-07-11 2005-02-17 Vaxin, Inc. Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax
PL1656095T3 (en) * 2003-08-18 2014-04-30 Novabay Pharmaceuticals Inc N,n-dihalogenated amino acids and derivatives
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
WO2007070301A2 (en) * 2005-12-05 2007-06-21 Regeneration Technologies, Inc. Vascular graft sterilization and decellularization
CN101190946A (en) * 2006-12-01 2008-06-04 中国人民解放军第二军医大学 Recombination plasmodium falciparum circumsporozoite surface protein and its preparation method and use
AU2009219358A1 (en) * 2008-02-28 2009-09-03 3M Innovative Properties Company Antibodies to Clostridium difficile spores and uses thereof
JO3421B1 (en) 2011-06-20 2019-10-20 H Lundbeck As Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007148065A2 (en) * 2006-06-23 2007-12-27 The Secretary Of State For Defence Antibody for anthrax

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JEDRZEJAS M J: "THE STRUCTURE AND FUNCTION OF NOVEL PROTEINS OF BACILLUS ANTHRACIS AND OTHER SPORE-FORMING BACTERIA: DEVELOPMENT OF NOVEL PROPHYLACTIC AND THERAPEUTIC AGENTS", CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, CRC PRESS, BOCA RATON, FL, US, vol. 37, no. 5, 1 January 2002 (2002-01-01), pages 339 - 373, XP009041491, ISSN: 1040-9238, DOI: DOI:10.1080/10409230290771537 *
KASPER D J ET AL: "Comparison of Plate Stamp and Glove Juice Methods for Assessing Removal of Clostridium difficile Spores from Hands", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 48, 2008, & 48TH ANNUAL INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY/46TH ANNUAL MEETING OF; WASHINGTON, DC, USA; 20081025,, pages 566, XP001525627, ISSN: 0733-6373 *
SEBAIHIA MOHAMMED ET AL: "The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome", NATURE GENETICS, vol. 38, no. 7, July 2006 (2006-07-01), pages 779 - 786, XP002609761, ISSN: 1061-4036 *
WELKOS SUSAN ET AL: "The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores", MICROBIOLOGY (READING), vol. 147, no. 6, June 2001 (2001-06-01), pages 1677 - 1685, XP002609760, ISSN: 1350-0872 *
WILLIAMSON P ET AL: "A new method for the quantitative investigation of cutaneous bacteria.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY DEC 1965 LNKD- PUBMED:5321315, vol. 45, no. 6, December 1965 (1965-12-01), pages 498 - 503, XP002609762, ISSN: 0022-202X *

Also Published As

Publication number Publication date
JP2012522010A (en) 2012-09-20
KR20110140128A (en) 2011-12-30
TW201039841A (en) 2010-11-16
EP2411410B1 (en) 2015-07-08
PT2411410E (en) 2015-10-09
AU2010241947B2 (en) 2014-01-16
US20100291100A1 (en) 2010-11-18
WO2010126670A2 (en) 2010-11-04
ES2544435T3 (en) 2015-08-31
BRPI1014121A2 (en) 2016-11-08
EP2411410A2 (en) 2012-02-01
DK2411410T3 (en) 2015-09-07
AU2010241947A1 (en) 2011-11-17
WO2010126670A9 (en) 2011-06-30
JP5911421B2 (en) 2016-05-18
CN102388064A (en) 2012-03-21
CA2756760A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
WO2010126670A3 (en) Compositions and methods for screening and using compounds antagonizing spore-surface interactions
Black et al. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases
EA200970985A1 (en) EXPRESSION SYSTEM
JP2016518833A5 (en)
UA100682C2 (en) Antibody which neutralizes human cytomegalovirus (hcmv) and use thereof
WO2006012366A3 (en) Methods for making and using recombinant bacillus thuringiensis spores
de Souza Duarte et al. Hyicin 4244, the first sactibiotic described in staphylococci, exhibits an anti-staphylococcal biofilm activity
WO2008084115A3 (en) Lactococcus promoters and uses thereof
MX2009012609A (en) Compositions and methods for producing bioactive fusion proteins.
EA201170961A1 (en) NEW BACILLUS THURINGIENSIS GENE WITH ACTIVITY AGAINST LEPIDOPTERA
WO2007133623A3 (en) Peptide diagnostic agent for lyme disease
Xin et al. Three novel lantibiotics, ticins A1, A3, and A4, have extremely stable properties and are promising food biopreservatives
EA201071400A1 (en) NEW BACILLUS THURINGIENSIS GENE WITH ACTIVITY AGAINST LEPIDOPTERAN (CABBILS)
WO2008127179A8 (en) Fusion protein vaccine
Clarke et al. Maturation of McjA precursor peptide into active microcin MccJ25
Qiu et al. Comparative proteomics analysis of Bacillus amyloliquefaciens SQR9 revealed the key proteins involved in in situ root colonization
CA2863661C (en) Diagnostic peptides for lyme disease
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
Wu et al. Molecular analysis and recombinant expression of bovine neutrophil β-defensin 12 and its antimicrobial activity
Carvalhais et al. Comparative proteomic and transcriptomic profile of Staphylococcus epidermidis biofilms grown in glucose-enriched medium
MX2010009071A (en) Isolated peptides having phospholipase inhibitory activity.
Vermeulen et al. Heterologous expression of the class IIa bacteriocins, plantaricin 423 and mundticin ST4SA, in Escherichia coli using green fluorescent protein as a fusion partner
Li et al. Promoter analysis and transcription regulation of fus gene cluster responsible for fusaricidin synthesis of Paenibacillus polymyxa SQR-21
WO2012024372A3 (en) Novel bacillus thuringiensis gene with coleopteran activity
Mokhtar et al. The discovery of new antilisterial proteins from Paenibacillus polymyxa Kp10 via genome mining and mass spectrometry

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080014098.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10745031

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 7055/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2756760

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012502303

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010745031

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117025319

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2010241947

Country of ref document: AU

Date of ref document: 20100326

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1014121

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI1014121

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1014121

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110926